Predilife: 2026 Half-Year Results and Financial Challenges

Predilife, specializing in disease risk prediction, has published its 2026 half-year results. Revenue reached €576,547, marking an increase compared to €392,773 in 2025. Despite a net loss of €1,337,198, a notable improvement compared to 2025 is due to the refocusing on MammoRisk.

Cash, including some receivables from the Public Treasury, amounts to approximately 100,000 euros, providing financial visibility until February 2027. However, the company remains under receivership proceedings, this period having been extended by six months by the Commercial Court of Créteil.

Regarding DenSeeRisk, FDA approval is in progress, with a file to be resubmitted within two months after requested adjustments, particularly related to cybersecurity.